1. Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies

   • David J. Stewart
   • M. Christine Cripps
   • M. Christine Cripps

   ORIGINAL ARTICLE Pages: 1 - 8

2. In vitro metabolism by mouse and human liver preparations of halomon, an antitumor halogenated monoterpene

   • Merrill J. Egorin
   • D. Marc Rosen
   • Julie L. Eiseman

   ORIGINAL ARTICLE Pages: 9 - 14

3. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer

   • E. Suonio
   • P. Lipponen
   • L. Tuomisto

   ORIGINAL ARTICLE Pages: 15 - 21

4. Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues

   • Garth Powis
   • Alfred Gallegos
   • John Worzalla

   ORIGINAL ARTICLE Pages: 22 - 28

5. Comparative disposition of the antineoplastic agent 9-nitrocamptothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution

   • Ahmed E. Ahmed
   • Sam Jacob
   • John S. Stehlin Jr

   ORIGINAL ARTICLE Pages: 29 - 36

6. Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays

   • Narima M. Lopes
   • Herbert P. Miller
   • Bijoy K. Bhuyan

   ORIGINAL ARTICLE Pages: 37 - 47

7. Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats

   • Jan H. M. Schellens
   • Wim Van de Vrie
   • Alexander M. M. Eggermont

   ORIGINAL ARTICLE Pages: 48 - 52

8. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer

   • Paul E. Goss
   • Sheldon Fine
   • Kathleen I. Pritchard

   ORIGINAL ARTICLE Pages: 53 - 60

9. Diversity of metallothionein content and subcellular localization in the National Cancer Institute tumor panel

   • Elizabeth S. Woo
   • Anne Monks
   • John S. Lazo

   ORIGINAL ARTICLE Pages: 61 - 68

10. Pharmacologic effects of paclitaxel in human bladder tumors

    • Jessie L.-S. Au
    • John Kalns
    • M. Guillaume Wientjes

    ORIGINAL ARTICLE Pages: 69 - 74

11. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study

    • D. R. Gandara
    • Martin J. Edelman
    • Robert B. Livingston

    ORIGINAL ARTICLE Pages: 75 - 78

12. Selective inhibition of oncogenic ras-p21 in vivo by agents that block its interaction with jun-N-kinase (JNK) and jun proteins. Implications for the design of selective chemotherapeutic agents

    • Shazia Amar
    • Albert Glozman
    • Matthew R. Pincus

    ORIGINAL ARTICLE Pages: 79 - 85

13. Phase I study of vinorelbine and paclitaxel in small-cell lung cancer

    • Rosario Vincenzo Iaffaioli
    • Gaetano Facchini
    • Rosario Vincenzo Iaffaioli

    CLINICAL TRIAL REPORT Pages: 86 - 90